UC Davis Reading Center
The UC Davis Retinal Reading Center provide comprehensive services for interpreting and analyzing data or images from optical coherence tomography (OCT), color fundus photographs (CFP), fluorescein angiography (FA), infrared reflective (IR), fundus autofluorescence (FAF) including quantitative autofluorescence (qAF), and OCT angiography (OCT-A) from various platforms. Our services support clinical research in various sectors of ophthalmology including retina, glaucoma, cornea, and neuro-ophthalmic studies. Our reading center ensures rigorous quality control, use of validated and reproducible measures, secure data storage and transfer, as well as training, certification, and feedback for ophthalmic photographers and technicians. The Reading Center was under the management of Dr. John L. Keltner, MD and John S. Werner, PhD. Today, Dr. Glenn Yiu serve as the director of the UC Davis Reading Center.
Past studies:
- Ocular Hypertension Treatment Study (OHTS) - The largest glaucoma clinical trial to date that evaluated ocular hypertension and open-angle glaucoma progression in 1636 individuals, with nearly 70,000 visual fields analyzed.
- Optic Neuritis Treatment Trial (ONTT) - This randomized study of 448 patients assessed the role of oral steroids and neuroimaging in the management of optic neuritis. Since 1988, UC Davis has served as the reading center for the 15-year follow-up to this trial and evaluated 18,000 visual fields.
Recent and active studies:
- SHORE Study - We analyzed OCT images from the phase 4, randomized, open-label study comparing intravitreal ranibizumab regimens for treatment of retinal vein occlusions with macular edema.
- TANZANITE Study - We evaluated choroidal and suprachoroidal changes in a phase 2 randomized trial of suprachoroidal triamcinolone and intravitreal aflibercept for macular edema from retinal vein occlusions.
- METforMIN Study - We measured geographic atrophy area in a randomized trial for an oral medication for treatment of end-stage nonexudative age-related macular degeneration.
- PREVENT Study - We analyzed CFP, FA, and FAF images for a prospective, randomized study evaluating prophylactic ranibizumab for prevention of choroidal neovascularization in non-neovascular fellow eyes of patients with unilateral neovascular AMD.
Publications:
Spectral-Domain OCT Predictors of Visual Outcomes after Ranibizumab Treatment for Macular Edema Resulting from Retinal Vein Occlusion. Ophthalmol Retina. 2020 Jan;4(1):67-76. doi: 10.1016/j.oret.2019.08.009. Epub 2019 Aug 28. PubMed PMID: 31669329; PubMed Central PMCID: PMC6944743.
Choroidal Changes After Suprachoroidal Injection of Triamcinolone Acetonide in Eyes With Macular Edema Secondary to Retinal Vein Occlusion. Am J Ophthalmol. 2018 Feb;186:144-151. doi: 10.1016/j.ajo.2017.11.020. Epub 2017 Dec 2. PubMed PMID: 29199012; PubMed Central PMCID: PMC5805638.
Visual field quality control in the Ocular Hypertension Treatment Study (OHTS). J Glaucoma. 2007 Dec;16(8):665-9. doi: 10.1097/IJG.0b013e318057526d. PubMed PMID: 18091452.
High- and low-risk profiles for the development of multiple sclerosis within 10 years after optic neuritis: experience of the optic neuritis treatment trial. Arch Ophthalmol. 2003 Jul;121(7):944-9. doi: 10.1001/archopht.121.7.944. PubMed PMID: 12860795.
Baseline visual field characteristics in the ocular hypertension treatment study. Ophthalmology. 2002 Mar;109(3):432-7. doi: 10.1016/s0161-6420(01)00948-4. PubMed PMID: 11874743.
Quality control functions of the Visual Field Reading Center (VFRC) for the Optic Neuritis Treatment Trial (ONTT). Control Clin Trials. 1993 Apr;14(2):143-59. doi: 10.1016/0197-2456(93)90016-7. PubMed PMID: 8500303.